Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artesunate for steroid-refractory chronic graft-versus-host disease after allo-HSCT
ChiCTR2500113111Phase 4Not yet recruiting
- Sponsor
- Xinqiao Hospital
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artesunate in chronic graft-versus-host disease (cGVHD), sponsored by Xinqiao Hospital. Primary endpoint: Overall response rate at 6 months. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
artesunate
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ChiCTR2500113111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113111.